Surveillance Recommendations for Testicular Cancer After Orchiectomy
For stage I testicular cancer after orchiectomy, surveillance protocols differ significantly between seminoma and non-seminomatous germ cell tumors (NSGCT), with seminoma requiring less frequent monitoring focused primarily on imaging, while NSGCT demands intensive serum tumor marker surveillance combined with cross-sectional imaging.
Stage I Seminoma Surveillance Protocol
For patients with clinical stage I seminoma choosing surveillance after orchiectomy, the following schedule should be implemented 1:
Years 1-2:
- History and physical examination every 4-6 months
- Cross-sectional imaging (CT or MRI) of abdomen ± pelvis every 4-6 months
- Serum tumor markers (AFP, β-HCG, LDH) as clinically indicated only
- Chest imaging only as clinically indicated
Years 3-5:
- History and physical examination every 6-12 months
- Cross-sectional imaging of abdomen ± pelvis every 6-12 months
- Serum markers as clinically indicated
Beyond 5 Years:
- Annual follow-up may be performed based on clinical concerns
- Risk of late relapse after 5 years is ≤1% 1
Key Point: For seminoma, the majority of relapses (>90%) are detected on abdominal-pelvic imaging rather than by tumor markers or physical examination 1. Recent evidence demonstrates that physical examination alone rarely identifies relapses in the modern era (0.3% in contemporary cohorts) 2, though it remains part of guideline recommendations.
Stage I NSGCT Surveillance Protocol
For stage I NSGCT, surveillance requires more intensive monitoring due to the 20-30% relapse risk 1:
Year 1:
- Physical examination every 2-3 months
- Serum tumor markers (AFP, β-HCG ± LDH) every 2-3 months
- Radiologic assessment (chest X-ray and CT abdomen/pelvis) every 3-6 months starting at 3 months post-orchiectomy
Year 2:
- Physical examination every 2-4 months
- Serum tumor markers every 2-4 months
- Imaging every 4-12 months
Year 3:
- Physical examination every 4-6 months
- Serum tumor markers every 4-6 months
- Imaging once during the year
Years 4-5:
- Physical examination every 6-12 months
- Serum tumor markers every 6-12 months
- Imaging once in year 4 or 5
Critical Modification for High-Risk Patients: Men with lymphovascular invasion should be imaged at shorter intervals within the recommended ranges 1.
Important Clinical Considerations
Relapse Detection Methods:
- NSGCT: Approximately 50% of relapses are detected by rising tumor markers alone, 24% by markers alone, 60% by imaging alone, and 15% by combined imaging and markers 2
- Seminoma: Imaging detects the vast majority of relapses; tumor markers have limited utility 1
Chest X-Ray Controversy:
Recent evidence demonstrates that routine chest X-rays no longer have value in stage I testicular cancer surveillance 3. In a cohort of 1,447 patients with 159 relapses, not a single relapse was identified on chest X-ray that wasn't already detected by CT or tumor markers. However, current guidelines still include chest imaging as part of comprehensive surveillance protocols 1.
Late Relapse Risk:
- The actuarial risk of relapse between 5-10 years is approximately 4% for seminoma 4
- Late relapses beyond 5 years do occur but are uncommon (≤1% risk) 1
- Patients should be informed of this small but clinically significant late relapse risk 1
Management of Relapse:
Patients who relapse on surveillance should be fully restaged and treated based on their TNM-s status 1. The prognosis for relapsed stage I disease remains excellent, with cancer-specific survival >99% for seminoma 5 and overall survival 98.25% at 20 years for NSGCT 6.
Survivorship Monitoring Beyond Cancer Surveillance
Hypogonadism Screening:
Monitor for signs and symptoms of hypogonadism; if present, measure serum AM testosterone and luteinizing hormone levels 1.
Cardiovascular Risk:
Patients treated with radiotherapy or chemotherapy have elevated cardiovascular disease risk and should establish regular primary care for monitoring of modifiable risk factors (diet, exercise, smoking, lipids, blood pressure, glucose) 1.
Secondary Malignancy Risk:
Patients treated with radiotherapy or chemotherapy should be counseled about elevated risk of secondary malignancies and maintain regular follow-up 1.
The surveillance approach avoids overtreatment in 70-80% of seminoma patients and 70-80% of NSGCT patients who will never relapse, while maintaining near-perfect survival rates through early detection and salvage therapy when needed 5, 6.